Chemomab Therapeutics Ltd. — Form SCHEDULE 13D
Filed July 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 72/100
What the filing says
HBM Healthcare Investments (Cayman) Ltd., holding 18.2M Chemomab ordinary shares (plus 62.8M shares underlying prefunded warrants), entered a shareholder support agreement dated July 6, 2026, to vote all its shares in favor of Scipher Medicine Corporation's acquisition of Chemomab. HBM commits to vote for the merger and related transactions, and against competing proposals, with an irrevocable proxy to Scipher if voting deadlines are missed. HBM also must exercise its prefunded warrants within 70 days and increase beneficial ownership limits to 19.99%.
Why this rating
Large shareholder lock-up supporting merger is material to deal certainty but typical M&A governance; no dollar amount or deal terms disclosed; HBM's ~81M total shares (18.2M + 62.8M warrant shares) likely substantial percentage of Chemomab's float, making voting commitment strategically important but not company-altering on its own.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.